Generic Equetro Availability
EQUETRO (carbamazepine - capsule, extended release; oral)
Manufacturer: VALIDUS PHARMS INC
Approval date: December 10, 2004
Strength(s): 100MG, 200MG, 300MG [RLD]
Has a generic version of Equetro been approved?
No. There is currently no therapeutically equivalent version of Equetro available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Equetro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
Issued: June 15, 1999
Inventor(s): Rudnic; Edward M. & Belendiuk; George W. & McCarty; John & Wassink; Sandra & Couch; Richard A.
Assignee(s): Shire Laboratories, Inc.
The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.Patent expiration dates:
- June 15, 2016✓
- June 15, 2016
Methods for the treatment of bipolar disorder using carbamazepine
Issued: December 20, 2005
Inventor(s): Kalali; Amir H. & Tulloch; Simon J.
Assignee(s): Shire Pharmaceutical Development Inc.
Carbamazepine, in extended release form, is useful in the treatment of patients suffering from bipolar disorder. In order to minimize the time it takes to reach efficacy, carbamazepine, in extended release form, can be administered to the patient at an initial daily dose which is then increased in daily increments until clinical efficacy is achieved.Patent expiration dates:
- May 19, 2024✓
- May 19, 2024
- Equetro Consumer Information (Drugs.com)
- Equetro sustained-release capsules Consumer Information (Wolters Kluwer)
- Equetro Consumer Information (Cerner Multum)
- Equetro Advanced Consumer Information (Micromedex)
- Carbamazepine Consumer Information (Drugs.com)
- Carbamazepine Consumer Information (Wolters Kluwer)
- Carbamazepine chewable tablets Consumer Information (Wolters Kluwer)
- Carbamazepine suspension Consumer Information (Wolters Kluwer)
- Carbamazepine sustained-release capsules Consumer Information (Wolters Kluwer)
- Carbamazepine sustained-release tablets Consumer Information (Wolters Kluwer)
- Carbamazepine Consumer Information (Cerner Multum)
- Carbamazepine Advanced Consumer Information (Micromedex)
- Carbamazepine AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|